Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

Part of paid clinical trials in Highland, California.

Sponsor
Incyte Corporation
Study ID
NCT00638378
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ruxolitinib — DRUG
    Ruxolitinib 25 mg tablets taken with water twice a day.

Study Details

This is a clinical trial of orally administered Ruxolitinib (INCB018424) in patients whose disease has progressed following 1 prior chemotherapy regimen (not including anti-androgens or ketoconazole) for metastatic, androgen-independent prostate cancer.

Key Dates

Start date
Feb 29, 2008
Status verified
Jan 2018
Primary completion
Jan 31, 2009
Completion
Jan 31, 2009

Study Design

Enrollment
22 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ruxolitinib
    Participants received ruxolitinib 25 mg orally twice daily in 12-hour intervals for 21-day cycles for as long as the study medication was tolerated and provided clinical benefit.

Primary Outcome Measure

Number of Participants With a Prostate-specific Antigen Response [ Time Frame: Assessed monthly from Baseline until the end of study (up to 8 months) ]

Locations (15)

FacilityCityStateZIPSite coordinators
-HighlandCalifornia--
-MontebelloCalifornia--
-Mountain ViewCalifornia--
-GalesburgIllinois--
-Overland ParkKansas--
-WichitaKansas--
-Grand RapidsMichigan--
-Jefferson CityMissouri--
-Great FallsMontana59405-
-Cherry HillNew Jersey--
-Staten IslandNew York--
-BismarckNorth Dakota--
-BethlehemPennsylvania--
-SumterSouth Carolina--
-LaceyWashington--

Find similar trials in Highland, CA

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology

Related Studies